Braxia Scientific EBIT

The latest EBIT for BRAX.CN is $-4.2M as of December 2023. That compares with $-12M in the prior-year period — up 64.9% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Braxia Scientific's historical trend and sector peers before judging valuation or financial health.

Over the past year, BRAX.CN's EBIT moved from $-12M to $-4.2M — a 64.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Braxia Scientific's operating scale or balance-sheet position.

Against Healthcare companies, BRAX.CN currently prints $-4.2M for EBIT, while the sector average sits near $110B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Braxia Scientific's growth, margins, and balance sheet.

A EBIT figure of $-4.2M for BRAX.CN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting BRAX.CN's EBIT ($-4.2M), review year-over-year change from $-12M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.